

Importance of Radiation Therapy in Multicomponent (Immunopolychemoradiotherapy) Treatment of Patients with Primary Mediastinal B-cell Large Lymphoma: the Review of the Literature and own Observations

N. V. Ilyin, J. N. Vinogradova, I. A. Shenderova,
M. M. Khodzhbekova, N. A. Kostenikov

Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg

Abstract

For the first time there are represented data on the role of radiation therapy and positron-emission tomography with ^{18}F -FDG (PET) in multicomponent immunochemoradiation treatment of 30 patients with primary mediastinal B-cell large lymphoma (PMLCL) who were followed-up in one centre – Russian Research Centre for Radiology and Surgical Technologies during 2005–2012. It is stated that medicinal component of the treatment (immunochemotherapy by R-CHOP scheme) results in a complete remission only in 37,9 % of patients. Radiation therapy given to all patients promotes more than twofold increase of complete remissions rate (uncertain complete); in irradiation twice a day no radiation pulmonitis revealed. PET assists to obtain more specific information concerning stages of the disease and improvement of the therapy effectiveness evaluation. Immunochemoradiation therapy of patients with PMLCL is an effective therapeutic approach and gives good late results: 5-year survival rate and survival free of progression are $89,1 \pm 7,5$ and $93,3 \pm 6,5$ % respectively. Radiation therapy is an important and necessary component of complex treatment of PMLCL patients.

Key words: Primary Mediastinal B-cell Large Lymphoma, Immunopolychemotherapy, Radiation Therapy.

References

1. *Aslanidi I. P., Muchortova O. U., Shurupova I. V.* Positron emission tomography for staging of patients with malignant lymphomas. *Clin. Oncohematol.* 2010. V. 3. N. 2. P. 119–129 (in Russian).
2. *Ilyin N. V., Tlostanova M. S., Khodzhbekova M. M. et al.* The clinical value of all body positron emission tomography with ^{18}F -FDG in malignant lymphomas. *Ibid.* 2010. V. 3. N. 2. P. 130–137 (in Russian).
3. *Mangasarova Ya. K., Misyurin A. V., Magomedova A. U. et al.* Molecular differential diagnosis distinguishes between primary mediastinal B-cell large lymphoma and diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes. *Clin. Oncohematol.* 2011. V. 4. N. 2. P. 142–145 (in Russian).
4. *Tumyan G. S., Kovrigina A. M., Kichigina M. U.* Primary mediastinal B-cell large lymphoma: diagnosis, clinic and treatment. *Actual. Oncol.* 2008. V. 10. N. 3. P. 66–68 (in Russian).
5. *Avigdor A., Sirotkon T., Shemtov N. et al.* The impact of R-VACOP-B and the prognostic significance of interim FDG-PET/CT on the outcome of patients with primary mediastinal

- large B-cell lymphoma – a retrospective analysis of a single center cohort. *Ann. Oncol.* 2011. N. 9. (Suppl. 4). P. 133.
6. *Cheson B., Pfistner B., Juweid M. et al.* Revised response criteria for malignant lymphoma. *J. Clin. Oncol.* 2007. V. 25. P. 579–586.
 7. *Dabrowska-Iwanica A., Giza A., Jurczak W. et al.* Treatment of primary mediastinal B-cell lymphoma – a multicenter retrospective analysis on behalf of the Polish Lymphoma Research Group. *Ann. Oncol.* 2011. N. 9. (Suppl. 4). P. 1165–1196.
 8. *Dunleavy K., Pittaluga S., Janik J. et al.* The addition of rituximab to dose-adjusted (DA) – epoch obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): of prospective study of 58 patients. *Ann. Oncol.* 2008. N. 19. (Suppl. 4). P. 96.
 9. *Dunleavy K., Pittaluga S., Shovin M. et al.* Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation. *Ibid.* 2011. N. 22. (Suppl. 4). P. 134.
 10. *Martelli M.* Rituximab does not improve survival of patients treated with M/VACOP-B plus radiotherapy in primary mediastinal large B-cell lymphoma (PMLBCL): an Italian phase II study of Intergruppo Italiano Linfomi (IIL) // *Ibid.* 2008. N. 19. (Suppl. 4). P. 96.
 11. *Martelli M., Ceriani L., Zinzani P. L. et al.* PET/CT response analysis in primary mediastinal diffuse large B-cell lymphoma (PMBL): preliminary results of the ielsg-26 study. *Ibid.* 2011. N. 22. (Suppl. 4). P. 133.
 12. *Martelli M., De Sanctis V., Finolezzi E. et al.* MACOP-B ± RITUXIMAB followed by involved mediastinal radiotherapy is a safe and high effective therapy for primary mediastinal large B-cell lymphoma (PMBL) long term results and late toxicity from of EPOCH-R without radiation single Italian center. *Ibid.* 2011. N. 22. (Suppl. 4). P. 134.
 13. *Savage K. J., Gaulard P.* Primary mediastinal (thymic) large B-cell lymphoma // *Extranodal lymphomas pathology and management.* Ed. Cavalli F, Stein H., Zucca E., Inborma UK, 2008. P. 196–211.
-

Authors

Ilyin Nikolay Vasilevich, M. D. Med., Professor, Chief Lymphoma Division, Department of Radiotherapy of Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg.
Address: 197758, Russia, Saint Petersburg, Pesochniy pos., Leningradskaya st., 70.
Phone number/fax: + 7 (812) 596-90-35. E-mail: ilyin_prof@mail.ru

Vinogradova Julia Nikolaevna, Ph. D. Med., Senior Researcher of Department of Radiotherapy of Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg.
Address: 197758, Russia, Saint Petersburg, Pesochniy pos., Leningradskaya st., 70.
Phone number: + 7 (812) 596-87-72. E-mail: vinogradova68@mail.ru

Shenderova Irina Aleksandrovna, Ph. D. Med., Nuclear Medicine Physician of Department of Radiotherapy of Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg.
Address: 197758, Russia, Saint Petersburg, Pesochniy pos., Leningradskaya st., 70.
Phone number: + 7 (812) 596-87-72. E-mail: i.shenderova@mail.ru

Khodzhibekova Malika Maratovna, Ph. D. Med., Nuclear Medicine Physician of Positron Emission Tomography, Department of Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg.
Address: 197758, Russia, Saint Petersburg, Pesochniy pos., Leningradskaya st., 70.
Phone number: +7 (812) 596-66-49, fax: +7 (812) 596-62-29. E-mail: malika_25@mail.ru

Kostenikov Nikolay Anatolyevich, M. D. Med., Chief Positron Emission Tomography, Department of Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russia, Saint Petersburg.
Address: 197758, Russia, Saint Petersburg, Pesochniy pos., Leningradskaya st., 70.
Phone number: +7 (812) 596-66-49.